Lilly's new antipsychotic gets CHMP nod; Teva puts $300M into Kowa JV;

> Eli Lilly's schizophrenia drug Zyphadera--the long-lasting, injectable form of the antipsychotic Zyprexa--got a recommendation from Europe's Committee for Medicinal Products for Human Use; next it faces final approval from the European Commission. Eli Lilly release

> Teva Pharmaceutical Industries inked its joint-venture deal with Japan's Kowa Pharma in a 50-50 deal capitalized with $300 million from the Israeli generics maker. Teva release

> The FDA warned five drugmakers--Shire, Johnson & Johnson, Novartis, Mallinckrodt, and Eli Lilly--that their promotional materials for ADHD meds were incomplete, false or misleading. Report

> India's Supreme Court told the government to appoint an external patent expert to help hear Novartis' appeal on the denial of a patent for its cancer drug Glivec (Gleevec). Report

> Covidien plans a $200 million restructuring program for 2009, hoping to achieve $50 million to $75 million in annual cost savings. Covidien release

> Noven Pharmaceuticals announced the appointment of Peter G. Amanatides as Vice President-Quality Assurance & Quality Control, effective immediately; he previously served at DSM Pharmaceuticals. Noven release

> Citing "historic instability in the market," Fluidigm announced today that it has withdrawn its registration statement for its IPO.

Emerging Drug Developer: KaloBios Pharmaceuticals

And Finally... Could anti-obesity meds be powerful antivirals, too? Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.